Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients.

David A. Lipson,Courtney Crim,Gerard J. Criner,Nicola C. Day,Mark T. Dransfield,David M G Halpin,MeiLan K. Han,C. Elaine Jones,Sally Kilbride,Peter Lange,David A. Lomas,Sally Lettis,Pamela Manchester,Neil Martin,Dawn Midwinter,Andrea Morris,Steve Pascoe,Dave Singh,Robert A. Wise,Fernando J. Martinez

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients.

2020

Rationale: The IMPACT trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with COPD...

Keywords:

Vilanterol
Fluticasone furoate
Anesthesia
Medicine
UMECLIDINIUM/VILANTEROL
COPD
Internal medicine
Fluticasone
Diabetes mellitus
pulmonary disease
copd patients
all cause mortality

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations